신경학적 바이오마커용 면역측정 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품별, 질환별, 용도별, 지역별, 경쟁별(2020-2030년)
Immunoassay for Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Disease, By Application, By Region and Competition, 2020-2030F
상품코드:1881612
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 신경학적 바이오마커용 면역측정 시장은 2024년에 6억 5,422만 달러로 평가되었으며, 2030년까지 CAGR 11.65%로 성장하여 12억 6,729만 달러에 달할 것으로 예측됩니다.
신경학적 바이오마커용 면역측정은 생물학적 샘플에서 신경 질환을 나타내는 특정 분자 간 상호 작용을 감지하고 정량화하도록 설계된 단백질 기반 검사를 포함합니다. 이러한 진단약의 세계 시장은 주로 신경퇴행성 질환의 유병률 증가와 조기 및 정확한 진단 도구에 대한 수요 증가에 의해 주도되고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
6억 5,422만 달러
시장 규모 : 2030년
12억 6,729만 달러
CAGR : 2025-2030년
11.65%
가장 빠르게 성장하는 부문
시약
최대 시장
북미
주요 시장 촉진요인
전 세계적으로 신경질환의 유병률이 증가하고 있는 것이 신경질환 바이오마커 면역측정 시장의 주요 촉진요인으로 작용하고 있습니다. 전 세계 인구의 고령화와 더불어 환경적 요인, 생활습관적 요인이 맞물려 신경퇴행성 질환의 부담이 증가하고 있습니다.
주요 시장 과제
신경질환 바이오마커 면역측정 시장은 엄격한 규제 장벽과 바이오마커 패널 표준화에 따른 고유한 복잡성으로 인해 큰 제약요인에 직면해 있습니다. 이러한 장벽은 새로운 측정법의 도입을 직접적으로 제약하고, 임상 현장에서의 보급을 복잡하게 만들고 있습니다.
주요 시장 동향
신경질환 바이오마커의 검출 및 분석 정확도 향상을 위한 인공지능(AI)의 통합은 신경질환 바이오마커용 면역측정 시장에 큰 영향을 미치고 있습니다. AI 알고리즘은 영상 데이터와 임상 기록을 포함한 복잡한 멀티모달 데이터를 처리하고, 신경 질환 진단에 필수적인 미묘한 바이오마커 패턴을 식별합니다.
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 신경학적 바이오마커용 면역측정 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
제품별(기기, 시약, 서비스)
질환별(알츠하이머병, 파킨슨병, 다발성 경화증, 기타)
용도별(체외진단, 조사)
지역별
기업별(2024)
시장 맵
제6장 북미의 신경학적 바이오마커용 면역측정 시장 전망
시장 규모 및 예측
시장 점유율과 예측
질환별
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 신경학적 바이오마커용 면역측정 시장 전망
시장 규모 및 예측
시장 점유율과 예측
질환별
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 신경학적 바이오마커용 면역측정 시장 전망
시장 규모 및 예측
시장 점유율과 예측
질병별
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 신경학적 바이오마커용 면역측정 시장 전망
시장 규모 및 예측
시장 점유율과 예측
질병별
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 신경학적 바이오마커용 면역측정 시장 전망
시장 규모 및 예측
시장 점유율과 예측
질병별
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병
제품 출시
최근 동향
제13장 세계의 신경학적 바이오마커용 면역측정 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 경쟁 구도
QIAGEN NV
Abbott Laboratories Inc.
Merck & Co., Inc.
Johnson & Johnson Services, Inc.
Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
Sysmex Corporation
F. Hoffmann La-Roche Ltd.
Nimble Therapeutics Inc.
HD Biosciences Co., Ltd.
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
KSM
영문 목차
영문목차
The Global Immunoassay for Neurological Biomarkers Market, valued at USD 654.22 Million in 2024, is projected to experience a CAGR of 11.65% to reach USD 1267.29 Million by 2030. Immunoassays for neurological biomarkers encompass protein-based tests designed to detect and quantify specific molecular interactions indicative of neurological disorders within biological samples. The global market for these diagnostics is primarily driven by the escalating prevalence of neurodegenerative conditions and the increasing demand for early and precise diagnostic tools.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 654.22 Million
Market Size 2030
USD 1267.29 Million
CAGR 2025-2030
11.65%
Fastest Growing Segment
Reagents
Largest Market
North America
Key Market Drivers
The increasing prevalence of neurological disorders globally constitutes a primary impetus for the immunoassay market for neurological biomarkers. The increasing longevity of the global population, coupled with environmental and lifestyle factors, contributes to a rising burden of neurodegenerative conditions. For instance, according to a study published in The Lancet in March 2024, the Global Burden of Disease, Injuries, and Risk Factors study 2021 revealed that 3.4 billion people, representing 43% of the world's population, were affected by neurological conditions in 2021. This widespread occurrence underscores an urgent clinical need for accurate and accessible diagnostic and monitoring tools, driving demand for advanced biomarker detection and effective therapeutic intervention development.
Key Market Challenges
The market for immunoassays in neurological biomarkers faces significant impedance due to stringent regulatory hurdles and the inherent complexity of standardizing biomarker panels. These obstacles directly constrain the introduction of novel assays and complicate their widespread clinical adoption. For instance, according to MedTech Europe's 2024 survey results, which includes data up to October 2023, certification and maintenance costs for in vitro diagnostic (IVD) devices under the new European IVD Regulation (IVDR) have escalated by 10% or more compared to previous directives, diverting substantial personnel and financial resources away from innovation and market expansion. This increase in regulatory burden and cost creates unpredictable timelines for manufacturers, particularly impacting smaller and medium-sized enterprises.
Key Market Trends
The integration of Artificial Intelligence for enhanced biomarker detection and analysis significantly impacts the immunoassay market for neurological biomarkers. AI algorithms process complex multimodal data, including imaging and clinical records, identifying subtle biomarker patterns crucial for diagnosing neurological disorders. This capability enables precise disease stratification and personalized therapeutic approaches. According to AdvaMed, in 2022, at least 91 new algorithms gained FDA approval in the first ten months, impacting diagnostic markets. Illustrating this, the University of Liverpool announced in October 2025 the development of a low-cost, handheld AI-powered blood test for early Alzheimer's detection. This innovation highlights AI's role in advancing accurate diagnostic tools.
Key Market Players
QIAGEN NV
Abbott Laboratories Inc.
Merck & Co., Inc.
Johnson & Johnson Services, Inc.
Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
Sysmex Corporation
F. Hoffmann La-Roche Ltd.
Nimble Therapeutics Inc.
HD Biosciences Co., Ltd.
Report Scope:
In this report, the Global Immunoassay for Neurological Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Immunoassay for Neurological Biomarkers Market, By Product:
Instruments
Reagents
Services
Immunoassay for Neurological Biomarkers Market, By Disease:
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Others
Immunoassay for Neurological Biomarkers Market, By Application:
In Vitro Diagnostics
Research
Immunoassay for Neurological Biomarkers Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Immunoassay for Neurological Biomarkers Market.
Available Customizations:
Global Immunoassay for Neurological Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Immunoassay for Neurological Biomarkers Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Instruments, Reagents, Services)
5.2.2. By Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Others)
5.2.3. By Application (In Vitro Diagnostics, Research)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Immunoassay for Neurological Biomarkers Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Disease
6.2.3. By Application
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Immunoassay for Neurological Biomarkers Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Disease
6.3.1.2.3. By Application
6.3.2. Canada Immunoassay for Neurological Biomarkers Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Disease
6.3.2.2.3. By Application
6.3.3. Mexico Immunoassay for Neurological Biomarkers Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Disease
6.3.3.2.3. By Application
7. Europe Immunoassay for Neurological Biomarkers Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Disease
7.2.3. By Application
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Immunoassay for Neurological Biomarkers Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Disease
7.3.1.2.3. By Application
7.3.2. France Immunoassay for Neurological Biomarkers Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Disease
7.3.2.2.3. By Application
7.3.3. United Kingdom Immunoassay for Neurological Biomarkers Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Disease
7.3.3.2.3. By Application
7.3.4. Italy Immunoassay for Neurological Biomarkers Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Disease
7.3.4.2.3. By Application
7.3.5. Spain Immunoassay for Neurological Biomarkers Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Disease
7.3.5.2.3. By Application
8. Asia Pacific Immunoassay for Neurological Biomarkers Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Disease
8.2.3. By Application
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Immunoassay for Neurological Biomarkers Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Disease
8.3.1.2.3. By Application
8.3.2. India Immunoassay for Neurological Biomarkers Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Disease
8.3.2.2.3. By Application
8.3.3. Japan Immunoassay for Neurological Biomarkers Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Disease
8.3.3.2.3. By Application
8.3.4. South Korea Immunoassay for Neurological Biomarkers Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Disease
8.3.4.2.3. By Application
8.3.5. Australia Immunoassay for Neurological Biomarkers Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Disease
8.3.5.2.3. By Application
9. Middle East & Africa Immunoassay for Neurological Biomarkers Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Disease
9.2.3. By Application
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Immunoassay for Neurological Biomarkers Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Disease
9.3.1.2.3. By Application
9.3.2. UAE Immunoassay for Neurological Biomarkers Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Disease
9.3.2.2.3. By Application
9.3.3. South Africa Immunoassay for Neurological Biomarkers Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Disease
9.3.3.2.3. By Application
10. South America Immunoassay for Neurological Biomarkers Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Disease
10.2.3. By Application
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Immunoassay for Neurological Biomarkers Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Disease
10.3.1.2.3. By Application
10.3.2. Colombia Immunoassay for Neurological Biomarkers Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Disease
10.3.2.2.3. By Application
10.3.3. Argentina Immunoassay for Neurological Biomarkers Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Disease
10.3.3.2.3. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Immunoassay for Neurological Biomarkers Market: SWOT Analysis
